NVS – Novartis AG
Novartis AGNVS
$140.25Name : Novartis AG
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $266,575,265,792.00
EPSttm : 6.62
Novartis AG
$140.25
0.53%$0.75
NVS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.28
Margin Of Safety %
6
Put/Call OI Ratio
2.11
EPS Next Q Diff
-0.31
EPS Last/This Y
1.64
EPS This/Next Y
0.99
Price
140.97
Target Price
153.34
Analyst Recom
2.53
Performance Q
-9.31
Upside
3.4%
Beta
0.43
Ticker: NVS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-09-08 | NVS | 137.74 | 2.14 | 2.15 | 135622 |
| 2026-09-09 | NVS | 137.5 | 1.91 | 1.51 | 139628 |
| 2026-09-10 | NVS | 137.48 | 1.81 | 11.22 | 139867 |
| 2026-09-11 | NVS | 137.2 | 1.80 | 1.49 | 140870 |
| 2026-09-14 | NVS | 139.02 | 1.79 | 0.72 | 142043 |
| 2026-09-15 | NVS | 138.67 | 1.79 | 1.07 | 142995 |
| 2026-09-16 | NVS | 138.57 | 1.78 | 0.50 | 143505 |
| 2026-09-17 | NVS | 140.95 | 1.77 | 2.33 | 143031 |
| 2026-09-18 | NVS | 140.36 | 1.80 | 1.09 | 145469 |
| 2026-09-21 | NVS | 141.03 | 2.18 | 0.90 | 112886 |
| 2026-09-22 | NVS | 141.26 | 2.14 | 2.45 | 115520 |
| 2026-09-23 | NVS | 142.18 | 2.12 | 0.62 | 115206 |
| 2026-09-24 | NVS | 143.55 | 2.11 | 1.69 | 115718 |
| 2026-09-25 | NVS | 145.46 | 2.12 | 1.10 | 116575 |
| 2026-09-28 | NVS | 146.9 | 2.11 | 1.95 | 116778 |
| 2026-09-29 | NVS | 145.7 | 2.13 | 0.51 | 117677 |
| 2026-09-30 | NVS | 142.56 | 2.13 | 2.64 | 117861 |
| 2026-10-01 | NVS | 141.03 | 2.15 | 2.98 | 118863 |
| 2026-10-02 | NVS | 140.96 | 2.11 | 3.18 | 118693 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-09-08 | NVS | 137.74 | -0.9 | 2068.4 | 8.80 |
| 2026-09-09 | NVS | 137.45 | -0.9 | 4660.9 | 8.80 |
| 2026-09-10 | NVS | 137.49 | -0.9 | 4720.2 | 8.80 |
| 2026-09-11 | NVS | 137.19 | -0.9 | 4570.6 | 8.80 |
| 2026-09-14 | NVS | 139.02 | -0.9 | 5224.6 | 8.80 |
| 2026-09-15 | NVS | 138.67 | -0.9 | 4893.2 | 8.80 |
| 2026-09-16 | NVS | 138.67 | -0.9 | 4893.2 | 8.80 |
| 2026-09-17 | NVS | 140.93 | -0.9 | 5196.5 | 8.85 |
| 2026-09-18 | NVS | 140.38 | -0.9 | 4979.8 | 8.85 |
| 2026-09-21 | NVS | 140.99 | -0.9 | 5205.3 | 8.85 |
| 2026-09-22 | NVS | 141.29 | -0.9 | 5020.5 | 8.85 |
| 2026-09-23 | NVS | 142.73 | -0.9 | 5120.5 | 8.85 |
| 2026-09-24 | NVS | 143.55 | -0.9 | 5043.1 | 8.85 |
| 2026-09-25 | NVS | 145.45 | -0.9 | 5174.4 | 8.85 |
| 2026-09-28 | NVS | 146.91 | -0.9 | 5110.1 | 8.85 |
| 2026-09-29 | NVS | 145.70 | -0.9 | 4766.4 | 8.85 |
| 2026-09-30 | NVS | 142.61 | -0.9 | 4515.0 | 8.85 |
| 2026-10-01 | NVS | 140.97 | -0.9 | 4708.7 | 8.85 |
| 2026-10-02 | NVS | 140.97 | -0.9 | 4576.8 | 8.85 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-09-08 | NVS | 0.00 | -0.21 | 0.27 |
| 2026-09-09 | NVS | 0.00 | -0.21 | 0.27 |
| 2026-09-10 | NVS | 0.00 | -0.21 | 0.27 |
| 2026-09-11 | NVS | 0.00 | -0.21 | 0.31 |
| 2026-09-14 | NVS | 0.00 | -0.11 | 0.31 |
| 2026-09-15 | NVS | 0.00 | -0.11 | 0.31 |
| 2026-09-16 | NVS | 0.00 | -0.11 | 0.31 |
| 2026-09-17 | NVS | 0.00 | -0.11 | 0.31 |
| 2026-09-18 | NVS | 0.00 | -0.11 | 0.31 |
| 2026-09-21 | NVS | 0.00 | -0.03 | 0.31 |
| 2026-09-23 | NVS | 0.00 | -0.03 | 0.31 |
| 2026-09-24 | NVS | 0.00 | -0.03 | 0.31 |
| 2026-09-25 | NVS | 0.00 | -0.03 | 0.28 |
| 2026-09-28 | NVS | 0.00 | 0.02 | 0.28 |
| 2026-09-29 | NVS | 0.00 | 0.02 | 0.28 |
| 2026-09-30 | NVS | 0.00 | 0.02 | 0.28 |
| 2026-10-01 | NVS | 0.00 | 0.02 | 0.28 |
| 2026-10-02 | NVS | 0.00 | 0.02 | 0.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.41
Avg. EPS Est. Current Quarter
2.23
Avg. EPS Est. Next Quarter
2.1
Insider Transactions
Institutional Transactions
0.02
Beta
0.43
Average Sales Estimate Current Quarter
14695
Average Sales Estimate Next Quarter
14987
Fair Value
149.87
Quality Score
93
Growth Score
82
Sentiment Score
65
Actual DrawDown %
17.3
Max Drawdown 5-Year %
-20.4
Target Price
153.34
P/E
21.27
Forward P/E
14.38
PEG
2.28
P/S
4.71
P/B
6.21
P/Free Cash Flow
15.39
EPS
6.63
Average EPS Est. Cur. Y
8.85
EPS Next Y. (Est.)
9.84
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
23.29
Relative Volume
1.07
Return on Equity vs Sector %
4.5
Return on Equity vs Industry %
-4.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
4576.8
◆
NVS
Healthcare
$141.01
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
40.6
Range 1M
13.9%
Sup Dist
0.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-1.9%
EPS NY
11.4%
52W%
39.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+30.4% upside
Upside
+30.4%
Quality
93
MoS
6%
NVS — P/E HistoricalDrug Manufacturers - General
Novartis AGSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75267
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
NVS
Latest News
—
Caricamento notizie per NVS…
stock quote shares NVS – Novartis AG Stock Price stock today
news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025
marketwatch NVS – Novartis AG yahoo finance google finance
stock history NVS – Novartis AG invest stock market
stock prices NVS premarket after hours
ticker NVS fair value insiders trading